Background Patients with systemic diseases are a group at high risk for the development of atherosclerosis and related complications. The most pressing issue remains the prevention of atherosclerosis in patients with systemic diseases. The role of L-arginin for prevention of atherosclerosis in patients with systemic diseases remains debatable.
Objectives We aimed to evaluate the effects of L-arginin for prevention of atherosclerosis in patients with systemic diseases.
Methods 30 patients (mean age – 48,73±1,25 years) with systemic diseases were enrolled. 17 (56,7%) patients received the standard treatment and L-arginin 4,2% 100 ml by infusion (1 group), while 13 (43,3%) (2 group) – received only the standard treatment for 2 weeks. Flow-mediated dilation (FMD) was assessed during reactive hyperemia and intima-media thicknes (IMT) by ultrasound.
Results FMD were decreased in 73,3% pts (mean level - 8,45±0,53%). Among them 10% pts with paradoxal vasoconstriction reaction. Increased IMT were in 30% pts (mean level - 0,91±0,02 mm). Among them 20% pts had plaque form. After 2 weeks of treatment with L-arginin 1 group had increased FMD by 22,2% (p<0,05), than 2 group (decrease by 8,7% (p<0,05)). 1 group had decreased IMT (p<0,05), than 2 group IMT were increase by (p<0,001)).
Conclusions L-arginin is effective and safe for the pts with systemic diseases. Its administration may provide benefits for the reduction of hospitalizations and mortality in its population.
Disclosure of Interest None declared